Impact of Heroin and HIV on Gut Integrity and Immune Activation.

3)-beta-D-glucan: a Folie a Deux contributing to HIV-associated immune activation. Front Immunol. 2019;10:465.
Dirajlal-Fargo S, Moser C, Rodriguez K, et al. Changes in the fungal marker beta-D-glucan after antiretroviral therapy and association with adiposity. Open Forum Infect Dis. 2019;6:ofz434.
Gianella S, Letendre SL, Iudicello J, et al. Plasma (1--> 3)-beta-D-glucan and suPAR levels correlate with neurocognitive performance in people living with HIV on antiretroviral therapy: a CHARTER analysis. J Neurovirol. 2019;25:837–843.
Mehraj V, Ramendra R, Isnard S, et al. Circulating (1-->3)-beta-D-glucan is associated with immune activation during human immunodeficiency virus infection. Clin Infect Dis. 2020;70:232–241.
Weiner LD, Retuerto M, Hager CL, et al. Fungal translocation is associated with immune activation and systemic inflammation in treated HIV. AIDS Res Hum Retroviruses. 2019;35:461–472.
El Kamari V, Moser C, Hileman CO, et al. Lower pretreatment gut integrity is independently associated with fat gain on antiretroviral therapy. Clin Infect Dis. 2019;68:1394–1401.
Allers K, Puyskens A, Epple HJ, et al. The effect of timing of antiretroviral therapy on CD4+ T-cell reconstitution in the intestine of HIV-infected patients. Mucosal Immunol. 2016;9:265–274.
Costiniuk CT, Angel JB. Human immunodeficiency virus and the gastrointestinal immune system: does highly active antiretroviral therapy restore gut immunity? Mucosal Immunol. 2012;5:596–604.
Mehandru S, Deren S, Kang SY, et al. Behavioural, mucosal and systemic immune parameters in HIV-infected and uninfected injection drug users. J Addict Res Ther. 2015;6:1–8.
Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018;138:1100–1112.
Thomas G, Tacke R, Hedrick CC, et al. Nonclassical patrolling monocyte function in the vasculature. Arterioscler Thromb Vasc Biol. 2015;35:1306–1316.
Salter ML, Lau B, Mehta SH, et al. Correlates of elevated interleukin-6 and C-reactive protein in persons with or at high risk for HCV and HIV infections. J Acquir Immune Defic Syndr. 2013;64:488–495.
Strickler HD, Blanchard JF, Vlahov D, et al. Elevated serum levels of neopterin but not beta 2-microglobulin in HIV-1-seronegative injecting drug users. AIDS. 1993;7:361–367.
Phillips KT, Stein MD. Risk practices associated with bacterial infections among injection drug users in Denver, Colorado. Am J Drug Alcohol Abuse. 2010;36:92–97.
Smith ME, Robinowitz N, Chaulk P, et al. High rates of abscesses and chronic wounds in community-recruited injection drug users and associated risk factors. J Addict Med. 2015;9:87–93.
Mars SG, Bourgois P, Karandinos G, et al. The textures of heroin: user perspectives on “black tar” and powder heroin in two U.S. Cities. J Psychoactive Drugs. 2016;48:270–278.
Summers PJ, Struve IA, Wilkes MS, et al. Injection-site vein loss and soft tissue abscesses associated with black tar heroin injection: a cross-sectional study of two distinct populations in USA. Int J Drug Pol. 2017;39:21–27.
Torka P, Gill S. Cotton fever: an evanescent process mimicking sepsis in an intravenous drug abuser. J Emerg Med. 2013;44:e385–e387.
Dwyer R, Topp L, Maher L, et al. Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users. Drug Alcohol Depend. 2009;100:9–16.
Siegel AJ, Mendelson JH, Sholar MB, et al. Effect of cocaine usage on C-reactive protein, von Willebrand factor, and fibrinogen. Am J Cardiol. 2002;89:1133–1135.
Kidd SE, Grey JA, Torrone EA, et al. Increased methamphetamine, injection drug, and heroin use among women and heterosexual men with primary and secondary syphilis—United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2019;68:144–148.
Petersen KL, Marsland AL, Flory J, et al. Community socioeconomic status is associated with circulating interleukin-6 and C-reactive protein. Psychosom Med. 2008;70:646–652.
Asher AK, Zhong Y, Garfein RS, et al. Association of self-reported abscess with high-risk injection-related behaviors among young persons who inject drugs. J Assoc Nurses AIDS Care. 2019;30:142–150.
Summers PJ, Hellman JL, MacLean MR, et al. Negative experiences of pain and withdrawal create barriers to abscess care for people who inject heroin. A mixed methods analysis. Drug Alcohol Depend. 2018;190:200–208. -->
Grant Information: R01 DA044576 United States DA NIDA NIH HHS; UL1 TR002548 United States TR NCATS NIH HHS
Substance Nomenclature: 0 (Biomarkers)
70D95007SX (Heroin)
9007-41-4 (C-Reactive Protein)
Entry Date(s): Date Created: 20220110 Date Completed: 20220502 Latest Revision: 20230926
Update Code: 20231215
PubMed Central ID: PMC8901022
DOI: 10.1097/QAI.0000000000002893
PMID: 35001040
Autor: Hileman CO; Division of Infectious Disease, Department of Medicine, MetroHealth Medical Center, Cleveland, OH.; Case Western Reserve University School of Medicine, Cleveland, OH., Bowman ER; Division of Medical Laboratory Science, School of Health and Rehabilitation Sciences, The Ohio State University, Columbus, OH; and., Gabriel J; Division of Medical Laboratory Science, School of Health and Rehabilitation Sciences, The Ohio State University, Columbus, OH; and., Kettelhut A; Division of Medical Laboratory Science, School of Health and Rehabilitation Sciences, The Ohio State University, Columbus, OH; and., Labbato D; Division of Infectious Disease, Department of Medicine and Pediatrics, University Hospitals Cleveland Medical Center, Cleveland, OH., Smith C; Division of Infectious Disease, Department of Medicine, MetroHealth Medical Center, Cleveland, OH., Avery A; Division of Infectious Disease, Department of Medicine, MetroHealth Medical Center, Cleveland, OH.; Case Western Reserve University School of Medicine, Cleveland, OH., Parran T; Case Western Reserve University School of Medicine, Cleveland, OH., Funderburg N; Division of Medical Laboratory Science, School of Health and Rehabilitation Sciences, The Ohio State University, Columbus, OH; and., McComsey GA; Case Western Reserve University School of Medicine, Cleveland, OH.; Division of Infectious Disease, Department of Medicine and Pediatrics, University Hospitals Cleveland Medical Center, Cleveland, OH.
Jazyk: angličtina
Zdroj: Journal of acquired immune deficiency syndromes (1999) [J Acquir Immune Defic Syndr] 2022 Apr 15; Vol. 89 (5), pp. 519-526.
DOI: 10.1097/QAI.0000000000002893
Abstrakt: Background: Altered gut integrity is central to HIV-related immune activation. Opioids may promote similar changes in gut permeability and/or increase systemic inflammation, potentially augmenting processes already occurring in people with HIV (PWH).
Setting: Urban hospital systems in Cleveland, Ohio, and surrounding communities.
Methods: This is a prospectively enrolled, cross-sectional study including people with and without HIV using heroin and people with and without HIV who have never used heroin, matched by age, sex, and CD4+ T-cell count (PWH only) to compare markers of gut integrity, microbial translocation, systemic inflammation, and immune activation.
Results: A total of 100 participants were enrolled. Active heroin use was associated with higher concentrations of lipopolysaccharide-binding protein (LBP), beta-D-glucan (BDG), high-sensitivity C-reactive protein (hsCRP), soluble tumor necrosis factor-α-receptors I and II, soluble CD163, inflammatory monocytes, and activated CD4+ lymphocytes in adjusted models. HIV status tended to modify the effect between heroin use and LBP, BDG, hsCRP, patrolling monocytes, and activated CD4+ lymphocytes (P < 0.15 for interactions); however, it was not as expected. The effect of heroin on these markers (except patrolling monocytes) was greatest among those without HIV rather than among those with HIV.
Conclusions: Heroin use is associated with heightened microbial translocation, systemic inflammation, and immune activation. Concurrent HIV infection in virologically suppressed individuals does not seem to substantially worsen the effects heroin has on these markers.
Competing Interests: C.O.H. has served as a consultant for Theratechnologies and Gilead and has received research grant support from Gilead. N.F. has served as a consultant for Gilead. G.A.M. has served as a consultant for Gilead, Merck, Theratechnologies, Jannsen, and GSK/ViiV and has received research grants from Roche, Genentech, Vanda, Astellas, Tetraphase, Gilead, Merck, and ViiV. The remaining authors have no conflicts of interest to disclose.
(Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze: MEDLINE
Externí odkaz: